Sergey L. Stvolinsky
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sergey L. Stvolinsky has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Olga I. Kulikova
Russian Center of Neurology and Neurosciences, 125367 Moscow, Russia
3 shared publications - Daniil Sergeevich Berezhnoy
Department of Pharmacology and Physiology, Georgetown University of Medical Center
2 shared publications - Denis A. Abaimov
Russian Center of Neurology and Neurosciences, 125367 Moscow, Russia
2 shared publications - Tatiana N. Fedorova
Russian Center of Neurology and Neurosciences, 125367 Moscow, Russia
2 shared publications - A. K. Sariev
FSAEI HE I. M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russian Federation (Sechenovskiy University)
1 shared publication A.S. Olshansky
Research Center of Neurology, Moscow, Russia
1 shared publication
Latest Publications
- Open Access
- 19 July 2023
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 2,p. 29-36
The pilot study of the basic pharmacokinetic properties of pyrrolylcarnosine — the new pyrrolic derivative of dipeptide carnosine
The experimental study of the pharmacokinetic characteristics of a new pyrrole derivative of carnosine, pyrrolylcarnosine, was carried out. Based on the results of the experiment, the basic pharmacokinetic parameters of the drug are expected. The tissues and organs bioavailability was studied. The tropism of pyrrolylcarnosine to the organs of elimination and the ability of pyrrolylcarnosine to penetrate into the heart muscle tissue were shown.
- 19 July 2023
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 2,p. 29-36
Open AccessThe pilot study of the basic pharmacokinetic properties of pyrrolylcarnosine — the new pyrrolic derivative of dipeptide carnosine
The experimental study of the pharmacokinetic characteristics of a new pyrrole derivative of carnosine, pyrrolylcarnosine, was carried out. Based on the results of the experiment, the basic pharmacokinetic parameters of the drug are expected. The tissues and organs bioavailability was studied. The tropism of pyrrolylcarnosine to the organs of elimination and the ability of pyrrolylcarnosine to penetrate into the heart muscle tissue were shown.
- Open Access
- 18 September 2019
- Published by Pirogov Russian National Research Medical University in Bulletin of Russian State Medical University
- No. 5,p. 45-50
Effects of carnosine and lipoic acid in the late stage of Parkinson’s disease in rats
The late stage of Parkinson’s disease is characterized by massive neuronal loss in the substantia nigra (SN) and degeneration of the dopaminergic innervation in the striatum. There is a need to assess the neuroprotective effect of antioxidants (AO) at this stage of the disease. The aim of our study was to assess the efficacy of two AO, carnosine and lipoic acid (LA), in the rat model of late-stage parkinsonism. The pathology was induced by a unilateral injection of 6-hydroxydopamine (6-OHDA) into the SN of the right brain hemisphere. AO were administered 4 times, starting on day 14 following the injection of the toxin. We investigated the effect of the injected drugs on the behavior of rats, the loss of neurons in the SN and the metabolism of biogenic neurotransmitter amines. Both AO dampened the development of 6-OHDA-induced neurological and behavioral symptoms. 6-OHDA induced a 90% drop (p = 0.01) in the levels of dopamine (DA) and its metabolites in the right striatum and caused death of over 95% of neurons (p = 0.01) in the SN of the right hemisphere (p = 0.01). AO did not have a significant effect on the number of neurons in the SN but caused an increase in the levels of DA metabolites, as compared to their levels in the animals exposed to 6-OHDA. Elevated DA (a 5.8-fold increase, p = 0.007) was observed only in the animals treated with carnosine. LA stimulated a 23% decline in serotonin levels (p = 0.06) and a 36% increase (p = 0.009) in its metabolite, 5-hydroxyindolacetic acid (5-HIAA). We conclude that although carnosine and LA did not have a direct neuroprotective effect, they could relieve the symptoms. This suggests that these AO could be used as an adjunctive component to antiparkinsonian therapy.
- 18 September 2019
- Published by Pirogov Russian National Research Medical University in Bulletin of Russian State Medical University
- No. 5,p. 45-50
Open AccessEffects of carnosine and lipoic acid in the late stage of Parkinson’s disease in rats
The late stage of Parkinson’s disease is characterized by massive neuronal loss in the substantia nigra (SN) and degeneration of the dopaminergic innervation in the striatum. There is a need to assess the neuroprotective effect of antioxidants (AO) at this stage of the disease. The aim of our study was to assess the efficacy of two AO, carnosine and lipoic acid (LA), in the rat model of late-stage parkinsonism. The pathology was induced by a unilateral injection of 6-hydroxydopamine (6-OHDA) into the SN of the right brain hemisphere. AO were administered 4 times, starting on day 14 following the injection of the toxin. We investigated the effect of the injected drugs on the behavior of rats, the loss of neurons in the SN and the metabolism of biogenic neurotransmitter amines. Both AO dampened the development of 6-OHDA-induced neurological and behavioral symptoms. 6-OHDA induced a 90% drop (p = 0.01) in the levels of dopamine (DA) and its metabolites in the right striatum and caused death of over 95% of neurons (p = 0.01) in the SN of the right hemisphere (p = 0.01). AO did not have a significant effect on the number of neurons in the SN but caused an increase in the levels of DA metabolites, as compared to their levels in the animals exposed to 6-OHDA. Elevated DA (a 5.8-fold increase, p = 0.007) was observed only in the animals treated with carnosine. LA stimulated a 23% decline in serotonin levels (p = 0.06) and a 36% increase (p = 0.009) in its metabolite, 5-hydroxyindolacetic acid (5-HIAA). We conclude that although carnosine and LA did not have a direct neuroprotective effect, they could relieve the symptoms. This suggests that these AO could be used as an adjunctive component to antiparkinsonian therapy.
- 1 June 2018
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 95, 254-259
Neuroprotective effect of the carnosine – α-lipoic acid nanomicellar complex in a model of early-stage Parkinson's disease
- 1 June 2018
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 95, 254-259
Neuroprotective effect of the carnosine – α-lipoic acid nanomicellar complex in a model of early-stage Parkinson's disease